Home/Filings/4/0001104659-24-101773
4//SEC Filing

MOULDER LEON O JR 4

Accession 0001104659-24-101773

CIK 0001953926other

Filed

Sep 19, 8:00 PM ET

Accepted

Sep 20, 6:34 PM ET

Size

12.7 KB

Accession

0001104659-24-101773

Insider Transaction Report

Form 4
Period: 2024-09-18
MOULDER LEON O JR
DirectorChief Executive Officer
Transactions
  • Purchase

    Common Stock

    2024-09-19$17.89/sh+5,000$89,4501,667,039 total(indirect: See Footnote)
  • Purchase

    Common Stock

    2024-09-20$17.88/sh+2,367$42,3221,669,406 total(indirect: See Footnote)
  • Purchase

    Common Stock

    2024-09-18$17.91/sh+10,000$179,1001,662,039 total(indirect: See Footnote)
  • Purchase

    Common Stock

    2024-09-20$18.97/sh+2,633$49,9481,672,039 total(indirect: See Footnote)
Holdings
  • Common Stock

    161,155
Footnotes (5)
  • [F1]The price reported is a weighted average price. These shares were purchased in multiple transactions ranging from $17.50 to $18.04, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
  • [F2]Leon O. Moulder, Jr. is the Managing Member of Tellus BioVentures LLC ("Tellus") and may be deemed to have sole voting and dispositive power over the shares held by Tellus. Mr. Moulder is the Issuer's chief executive officer and Chairman of its board of directors. Mr. Moulder disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
  • [F3]The price reported is a weighted average price. These shares were purchased in multiple transactions ranging from $17.64 to $18.00, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
  • [F4]The price reported is a weighted average price. These shares were purchased in multiple transactions ranging from $17.70 to $18.27, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
  • [F5]The price reported is a weighted average price. These shares were purchased in multiple transactions ranging from $18.35 to $19.24, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.

Issuer

Zenas BioPharma, Inc.

CIK 0001953926

Entity typeother

Related Parties

1
  • filerCIK 0001228865

Filing Metadata

Form type
4
Filed
Sep 19, 8:00 PM ET
Accepted
Sep 20, 6:34 PM ET
Size
12.7 KB